Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-04
2005-10-04
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255050, C514S256000, C514S269000, C514S272000, C544S122000, C544S295000, C544S296000, C544S310000, C544S311000, C544S317000
Reexamination Certificate
active
06951856
ABSTRACT:
The invention relates to novel aryl-ethene-sulfonamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
REFERENCES:
patent: 5292740 (1994-03-01), Burri et al.
patent: 5420129 (1995-05-01), Breu et al.
patent: 0 526 708 (1993-02-01), None
patent: 0 633 259 (1995-01-01), None
patent: 0 658 548 (1995-06-01), None
patent: 0 743 307 (1996-11-01), None
patent: 0 882 719 (1998-12-01), None
patent: 0 959 072 (1999-11-01), None
patent: WO 00/42035 (2000-07-01), None
patent: WO 00/52007 (2000-09-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Harada et al., Abstract (Ethenesulfonamide Derivatives, a Novel Class of Orally Active Endothelin-A Receptor Antagonists, Chem. Pharm. Bull., 49(5):606-612), May 2001.
Harada et al., CAPLUS Abstract 135:122462, 2001.
Schiffrin, Role of Endothelin-1 in Hypertension, Hypertension, Part II, pp. 876-881, Oct. 1999.
Arai et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec. 20-27; 348(6303):730-2.
Arogba, S. S. Synthesis of primin and miconinin an dtheir 3-methoxy isomers. Organic Preparations and Procedures Int., 1991, 23(5):639-643.
Bhaskar Reddy et al. Phosphorous, Sulfur and Silicon., 1993, 84:63-71.
Bhaskar Reddy et al., Indian J. Chem., 1995, 34B:816-822.
Breu et al. In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett. Nov. 15, 1993;334(2):210-4.
Culbertson et al. Some aromatic vinyl sulphonyl chlorides. J. Chem. Soc. (C), 1968, 992-993.
Douglas et al. Endothelin-1 does not mediate hypoxic vasoconstriction in canine isolated blood vessels: effect of BQ-123. Br J Pharmacol. Feb. 1993;108(2):418-21.
Fox et al. Highly active and selective catalysts for the formation of α-Aryl ketones. J. Am. Chem. Soc., 2000, 122:1360-1370.
Gohring et al. Development of a process to prepare 2-cyanopyrimidine on commercial scale. Chimia, 1996, 50:538-543.
Kameyama et al. Synthesis of substituted 1,3-Dienes by the Reaction of Alkenesulfonyl chlorides with olefins catalyzed by a ruthenium (II) complex. Bull. Chem. Soc. Jpn., 1988, 61:1231-1235.
Kohara et al. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem. Dec. 20, 1996;39(26)5228-35.
Lonchambon et al. Bull. Soc. Chim. Fr., 1981, II-71 (in French with English Summary).
March, J. Advanced Organic Chemistry. 4thEd., 1994, p. 499.
Matlack A.S. Preparation of ethenesulfonamide. J. Org. Chem., 1958, 23:729-31.
McMillen et al. Endothelins: polyfunctional cytokines. J Am Coll Surg. May 1995;180(5):621-37. Review.
Neidhart et al. Discovery of RO 48-5695: A potent mixed endothelin receptor antagonist optimized from Bosentan. Bioorg. Med. Chem. Lett. 1997, 7:2223-2228.
Neidhart et al. The discovery of nonpeptide endothelin receptor antagonists. Progression towards Bosentan. Chimia 1996, 50:519-524.
Nugent et al. Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV. J Med Chem. Sep. 24, 1998;41(20):3793-803.
Ogawa et al. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun. Jul. 15, 1991;178(1):248-55.
Ramana Reddy et al. A new route for the synthesis of styrylbenzylsulfones, precursors of 1-benzylsulfonyl-2-arylcyclopropanes. Phosphorous Sulfur and Silicon. 1990, 53:285-290.
Rubanyi et al. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. Sep. 1994;46(3):325-415. Review.
Sumner et al. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol. Nov. 1992;107(3):858-60.
Yanagisawa et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. Mar. 31, 1998;332(6163):411-5.
Bull. Chem Soc. Jpn., 1991, 64:1431.
Bolli Martin
Boss Christoph
Clozel Martine
Fischli Walter
Weller Thomas
Actelion Pharmaceuticals Ltd.
Gibbons Del Deo Dolan Griffinger & Vecchione
Rao Deepak
LandOfFree
Arylethene-sulfonamides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylethene-sulfonamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylethene-sulfonamides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435309